Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system that
causes significant disability and healthcare burden. The treatment of MS has evolved over …

There are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of
action currently approved by the US Food and Drug Administration for the treatment of …

Importance To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing
Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease …

Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …

Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are bioactive lipid molecules
that are ubiquitously expressed in the human body and play an important role in the immune …

Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by the
progressive loss of axonal myelin in several areas of the central nervous system (CNS) that …

Objective: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active
relapsing-remitting multiple sclerosis and inadequate response to prior therapy. Methods: In …

COVID-19 vaccination is recommended for multiple sclerosis patients. Disease-modifying
therapies can influence the safety and efficacy of COVID-19 vaccines. RNA, DNA, protein …

The immunomodulatory drug fingolimod (FTY720, Gilenya R) was approved for oral
treatment of relapsing-remitting multiple sclerosis, due to its impressive efficacy and good …